Skip to content

Sermorelin Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Sermorelin dosing should be individualized by a licensed healthcare provider based on the patient's age, body weight, baseline IGF-1 levels, and treatment goals. The following ranges are derived from clinical literature and prescribing conventions at compounding pharmacies:

  • Standard anti-aging and wellness range: 200 to 300 mcg administered subcutaneously at bedtime, 5 to 7 nights per week
  • Conservative starting dose: 100 to 200 mcg at bedtime for the first 2 to 4 weeks, titrated upward based on tolerance and clinical response
  • Higher-end clinical dosing: 300 to 500 mcg at bedtime, typically reserved for patients with documented low IGF-1 levels or poor initial response
  • Pediatric dosing (historical FDA-approved): 30 mcg/kg subcutaneously at bedtime, as per the original Geref labeling

Most protocols employ 5-nights-per-week dosing (weekdays on, weekends off) to balance therapeutic benefit with physiological rest periods. Some providers prescribe nightly dosing for the first 3 to 6 months before transitioning to a 5-on/2-off schedule.

Cycling is not universally required with sermorelin due to its axis-preserving mechanism, but some clinicians recommend periodic reassessment (every 3 to 6 months) with IGF-1 monitoring to adjust dosing. Unlike GH secretagogues that act on the ghrelin receptor, tolerance to sermorelin's GHRH receptor activation appears to develop slowly, if at all.

Frequently Asked Questions

Most anti-aging protocols use 200 to 300 mcg administered subcutaneously at bedtime, 5 nights per week. Dosing is individualized based on age, IGF-1 levels, and clinical response. A healthcare provider should determine the appropriate dose and monitor progress.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
  3. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
  6. FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(42):14219-14220.
  7. World Anti-Doping Agency. The 2025 Prohibited List International Standard.
  8. Sermorelin Acetate. RxList Drug Database.
  9. PubChem. Sermorelin (CID 16132413).
  10. Sermorelin. DrugBank (DB00010).

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”